Arizona
Cancer clinical trials in Arizona
298 cancer studies are recruiting participants at sites in 18 cities across Arizona as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every Arizona city with a recruiting study
By research area: Breast Cancer (78), Lung Cancer (74), Lymphoma (59), Prostate Cancer (39), Pancreatic Cancer (30), Melanoma (18).
Phoenix (123), Tucson (88), Scottsdale (82), Gilbert (43), Goodyear (27), Chandler (24), Kingman (15), Mesa (12), Glendale (10), Bullhead City (7), Casa Grande (2), Peoria (2), Tuscon (2), Chinle (1), Flagstaff (1), Prescott Valley (1), Surprise (1), Tempe (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Breast cancer: recently updated in Arizona
Basic details from each study's public record (the 12 most recently updated of 298). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Recruiting in
- Scottsdale · Tucson
- Registry record
- NCT05696626 · updated
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Gilbert
- Registry record
- NCT05894239 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Arizona on ClinicalTrials.gov.
Lung cancer: recently updated in Arizona
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Recruiting in
- Goodyear · Phoenix
- Registry record
- NCT07277413 · updated
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Recruiting in
- Phoenix · Tucson
- Registry record
- NCT07063745 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Arizona on ClinicalTrials.gov.
Prostate cancer: recently updated in Arizona
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Recruiting in
- Phoenix
- Registry record
- NCT04423211 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Arizona on ClinicalTrials.gov.
Melanoma: recently updated in Arizona
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Recruiting in
- Phoenix
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Arizona on ClinicalTrials.gov.
Lymphoma: recently updated in Arizona
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eastern Cooperative Oncology Group
- Recruiting in
- Phoenix · Tucson
- Registry record
- NCT06724237 · updated
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Recruiting in
- Phoenix
- Registry record
- NCT07221500 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Gilbert · Phoenix · Tucson
- Registry record
- NCT06717347 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Chandler · Glendale · Goodyear
- Registry record
- NCT06890884 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Arizona on ClinicalTrials.gov.
Pancreatic cancer: recently updated in Arizona
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
- Early Phase 1
- Ages 18 to 99
- All sexes
- Sponsor
- University of Arizona
- Recruiting in
- Tucson
- Registry record
- NCT07627191 · updated
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Recruiting in
- Chandler · Tucson
- Registry record
- NCT07522073 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Arizona on ClinicalTrials.gov.
Ask about studies in Arizona
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections